

of cancer by Sato and colleagues (42), who found that the frequency of MDSC in non-Hodgkin lymphoma patients was increased and inversely correlated with that of NK cells, not that of T cells (42). Other evidence that activated NK cells can lyse the MDSCs has been published by Gleason and colleagues (43). Even though NK cells and their expression of FcR γ III (CD16) are decreased in myelodysplastic syndromes (MDS) and inversely correlate with a substantial increase in MDSCs, the enhancement of CD16 signaling potently activates NK cells to lyse CD33⁺ MDS and MDSC targets (43). Although we suggest a novel role for *ex vivo*-activated NK cells in overcoming the negative function of immune suppressor cells, identification of the underlying mechanism will require further study. To this end, additional analysis of interactions between NK and Treg or MDSC cells in a cancer model will not only provide valuable information, but may also improve efficacy in anticancer immunotherapy.

Several studies have examined the role of chemokines secreted from NK cells in experimental tumor models (24). In one report, significant induction of MIG, IP-10, RANTES, MCP-1, and IL8 from NK cells following IL12 administration suggested a role for NK cells in the initiation of the chemokine response (28). However, less is known about the chemokine response after the direct administration of NK cells. In our system, we found elevated MIG, MCP-1, MIP-1 β , and RANTES concentrations, suggesting that activated NK cells secrete a broad array of T cell-attracting chemokines. These chemokines act together to recruit tumor-infiltrating T cells, resulting in a decreased incidence of recurrence and increased overall survival in cancer patients (28, 44–46). Moreover, our finding of secretion of T-cell-attracting chemokines following administration of activated NK cells suggests an additional mechanism through which T-cell infiltration to the tumor sites could be achieved.

In conclusion, the safety data for transplantation of MG4101 derived from unrelated random healthy donors will give

increased opportunities to select donors that have either maximum KIR incompatibility against recipients or a potent KIR B haplotype. To enhance clinical benefit, we are currently considering a phase II study including immunosuppressive chemotherapy followed by MG4101 treatment, based on previous successful results involving lymphodepleting preparative regimens (9).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: T.M. Kim, B. Keam, Y.K. Hwang, D.S. Heo
Development of methodology: O. Lim, T.M. Kim, H. Choi, H. Chung, B. Min, D.S. Heo
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Yang, O. Lim, T.M. Kim, Y.-O. Ahn, H. Chung, B. Min, J.H. Her, B. Keam, S.-H. Lee, D.-W. Kim, D.S. Heo
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Yang, O. Lim, T.M. Kim, H. Choi, B. Keam, D.S. Heo
Writing, review, and/or revision of the manuscript: Y. Yang, O. Lim, T.M. Kim, H. Choi, S.Y. Cho, B. Keam, D.S. Heo
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Yang, H. Choi, S.Y. Cho, B. Keam
Study supervision: D.S. Heo

Grant Support

This study was supported by grants from Green Cross Corporation, MOGAM Biotechnology Institute, and the Innovative Research Institute for Cell Therapy, Republic of Korea (A062260).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 29, 2015; revised September 11, 2015; accepted December 2, 2015; published OnlineFirst January 19, 2016.

References

- Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. *Blood* 1990;76:2421–38.
- Farag SS, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cells: biology and application in stem-cell transplantation. *Cytotherapy* 2002;4:445–6.
- Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. *Blood* 1999;94:333–9.
- Leung W. Infusions of allogeneic natural killer cells as cancer therapy. *Clin Cancer Res* 2014;20:3390–400.
- Giebel S, Locatelli F, Lamparelli T, Velardi A, Davies S, Frumento G, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. *Blood* 2003;102:814–9.
- Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. *Blood* 2011;118:3273–9.
- Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevas CN, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. *Cancer Immunol Immunother* 2010;59:1781–9.
- Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. *Blood* 2007;110:433–40.
- Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. *Immunotherapy* 2011;3:1445–59.
- Joncker NT, Fernandez NC, Treiner E, Vivier E, Raulet DH. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. *J Immunol* 2009;182:4572–80.
- Miller JS, Soignier Y, Panoskaltis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. *Blood* 2005;105:3051–7.
- Lim O, Lee Y, Chung H, Her JH, Kang SM, Jung MY, et al. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo. *PLoS One* 2013;8:e53611.
- Grieco A, Long CJ. Investigation of the Karnofsky Performance Status as a measure of quality of life. *Health Psychol* 1984;3:129–42.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 1982;5:649–55.
- Trotti A, Colevas AD, Setzer A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. *Semin Radiat Oncol* 2003;13:176–81.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009;45:228–47.
- Cheson BD, Pfister B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. *J Clin Oncol* 2007;25:579–86.

Yang et al.

18. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. *Diabetes* 2009;58:652–62.
19. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. *Cancer Res* 2005;65:3044–8.
20. Bein G, Glaser R, Kirchner H. Rapid HLA-DRB1 genotyping by nested PCR amplification. *Tissue Antigens* 1992;39:68–73.
21. Karimi MA, Bryson JL, Richman LP, Fesnak AD, Leichner TM, Satake A, et al. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT. *Blood* 2015;125:3655–63.
22. Krebs P, Barnes MJ, Lampe K, Whitley K, Bahjat KS, Beutler B, et al. NK-cell-mediated killing of target cells triggers robust antigen-specific T-cell-mediated and humoral responses. *Blood* 2009;113:6593–602.
23. Barber LD, Madrigal JA. Exploiting beneficial alloreactive T cells. *Vox Sang* 2006;91:20–7.
24. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. *Trends Immunol* 2001;22:633–40.
25. Wright GP, Ehrenstein MR, Stauss HJ. Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity. *Expert Rev Clin Immunol* 2011;7:213–25.
26. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* 2009;9:162–74.
27. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaehri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood* 2001;97:3146–51.
28. Roda JM, Parihar R, Magro C, Nuovo GJ, Tridandapani S, Carson WE 3rd. Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells. *Cancer Res* 2006;66:517–26.
29. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. *Br J Haematol* 2008;143:641–53.
30. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR, Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). *Immunol Rev* 2014;258:45–63.
31. Albertsson PA, Basse PH, Hokland M, Goldfarb RH, Nagelkerke JF, Nannmark U, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. *Trends Immunol* 2003;24:603–9.
32. Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, et al. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells. *In Vivo* 2000;14:651–8.
33. Bruno A, Ferlazzo G, Albini A, Noonan DM. A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. *J Natl Cancer Inst* 2014;106:dju200.
34. Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. *J Clin Invest* 2003;112:1862–70.
35. Khan IA, Thomas SY, Moretto MM, Lee FS, Islam SA, Combe C, et al. CCR5 is essential for NK cell trafficking and host survival following *Toxoplasma gondii* infection. *PLoS Pathog* 2006;2:e49.
36. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. *Nat Immunol* 2004;5:1260–5.
37. Huang D, Shi FD, Jung S, Pien GC, Wang J, Salazar-Mather TP, et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. *FASEB J* 2006;20:896–905.
38. Liu C, Luo D, Reynolds BA, Meher G, Katritzky AR, Lu B, et al. Chemokine receptor CXCR3 promotes growth of glioma. *Carcinogenesis* 2011;32:129–37.
39. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, et al. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. *J Exp Med* 1998;187:2009–21.
40. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). *J Exp Med* 1987;166:1084–97.
41. Pedroza-Pacheco I, Madrigal A, Saudemont A. Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. *Cell Mol Immunol* 2013;10:222–9.
42. Sato Y, Shimizu K, Shinga J, Hidaka M, Kawano F, Kakimi K, et al. Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma. *Oncoimmunology* 2015;4:e995541.
43. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. *Blood* 2014;123:3016–26.
44. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. *J Immunol* 1998;161:6433–8.
45. Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T. IgE-mediated activation of NK cells through Fc gamma RIII. *J Immunol* 2003;170:3054–8.
46. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, et al. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. *Eur J Immunol* 2001;31:3016–25.

Cancer Immunology Research

Phase I Study of Random Healthy Donor–Derived Allogeneic Natural Killer Cell Therapy in Patients with Malignant Lymphoma or Advanced Solid Tumors

Yaewon Yang, Okjae Lim, Tae Min Kim, et al.

Cancer Immunol Res 2016;4:215-224. Published OnlineFirst January 19, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-15-0118](https://doi.org/10.1158/2326-6066.CIR-15-0118)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2016/01/19/2326-6066.CIR-15-0118.DC1>

Cited articles This article cites 46 articles, 20 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/4/3/215.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cancerimmunolres.aacrjournals.org/content/4/3/215.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/4/3/215>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.